Use and assessment of diagnostic and predictive markers in breast pathology

Current Diagnostic Pathology

Volumn 13, Issue 2, 2007, Pages 126-134

  Walker, Rosemary A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Breast cancer; Ductal carcinoma in situ; HER 2; Myoepithelium; Oestrogen receptor; p63; Smooth muscle myosin heavy chain

Indexed keywords

BIOCHEMICAL MARKER; CADHERIN; CALDESMON; CALPONIN; COLLAGEN TYPE 4; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FIBRONECTIN; LAMININ; PROGESTERONE RECEPTOR; PROTEIN P63; PROTEIN S 100; SMOOTH MUSCLE ACTIN; SMOOTH MUSCLE ANTIBODY; TUMOR MARKER; UVOMORULIN;

ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DISEASE; BREAST EPITHELIUM; BREAST TUMOR; CARCINOMA IN SITU; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MYOEPITHELIUM; ONCOGENE NEU; PROTEIN EXPRESSION; SMOOTH MUSCLE; TUMOR CELL;

EID: 34047235657     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdip.2006.12.001     Document Type: Article

References (49)

1. Zhang R.R., Man Y.-G., Vang R., et al. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res 5 (2003) 151-156
2. Yaziji H., Gown A.M., and Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol 7 (2000) 100-109
3. Lontine J.A., Pincus G.S., Fujiwara K., and Corson J.M. Immunohistochemical localisation of smooth muscle myosin in normal human tissues. J Histochem Cytochem 33 (1985) 179-184
4. Ohyabu I., Takasaki T., Akiba S., et al. Immunohistochemical studies on expression of human vascular smooth muscle myosin heavy chain isoforms in normal mammary glands, benign mammary disorders and mammary carcinomas. Pathol Int 48 (1998) 433-439
5. Foschini M.P., Scarpellini F., Gown A.M., and Eusebi V. Differential expression of myoepithelial markers in salivary, sweat and mammary glands. Int J Surg Pathol 8 (2000) 29-37
6. Frid M.G., Shekhonin S.V., Koteliansky V.E., and Glukhova M.A. Phenotypic changes of smooth muscle cells during developments; late expression of heavy caldesmon and calponin. Dev Biol 153 (1992) 185-193
7. Lazard D., Sastre X., Frid M.G., Glukhova M.A., Thiery J.P., and Koteliansky V.E. Expression of smooth muscle specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc Natl Acad Sci USA 90 (1993) 999-1003
8. Dairkee S.H., Blayney C., Smith H.S., and Hackett A.J. Monoclonal antibody that defines human myoepithelium. Proc Natl Acad Sci USA 82 (1985) 7409-7413
9. Nagle R.B., Bocker W., Davis J.R., et al. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 34 (1986) 869-881
10. Joshi M.G., Lee A.K., Pedersen C.A., Schnitt S., Camus M.G., and Hughes K.S. The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast. Mod Pathol 9 (1996) 57-62
11. Dwarakanath S., Lee A.K., Delellis R.A., Silverman M.L., Frasca L., and Wolfe H.J. S100 protein positivity in breast carcinomas: a potential pitfall in diagnostic immunohistochemistry. Hum Pathol 18 (1987) 1144-1148
12. Gusterson B.A., Monaghan P., Manhendran R., Ellis J., and O'Hare M.J. Identification of myoepithelial cells in human and rat breasts by anti-common acute lymphoblastic leukaemia antigen antibody A12. J Natl Cancer Inst 77 (1986) 343-349
13. Moritani S., Kushima R., Sugihara H., Bamba H., Kobayashi T., and Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 15 (2002) 397-405
14. Kovács A., and Walker R.A. P-cadherin as a marker in the differential diagnosis of breast lesions. J Clin Pathol 56 (2003) 139-141
15. Barbareschi M., Pecciarini L., Cangi M.G., et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25 (2001) 1056-1060
16. Werling R.W., Hwang H., Yaziji H., and Gown A.M. Immunohistochemical distinction of invasive from non-invasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27 (2003) 82-90
17. Simpson P.T., Gale T., Reis-Filho J.S., et al. Distribution and significance of 14-3-3 sigma, a novel myoepithelial marker, in normal, benign and, malignant breast tissue. J Pathol 202 (2004) 274-285
18. Reis-Filho J.S., Milanezi F., Silva P., and Schmitt F.C. Maspin expression in myoepithelial tumours of the breast. Pathol Res Pract 197 (2002) 817-821
19. Bose S., DeRosa C.M., and Ozzello L. Immunostaining of type IV collagen and smooth muscle actin as an aid in the diagnosis of breast lesions. Breast J 5 (1999) 194-201
20. Otterbach F., Bankfalvi A., Bergher S., Decker T., Krech R., and Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 37 (2000) 232-240
21. Moll R., Mitze M., Frixen U.H., and Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 143 (1993) 1731-1742
22. De Leeuw W.J.F., Berx G., Vos C.H.J., et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183 (1997) 404-411
23. Collins L.C., Carlo V.P., Hwang H., Barry T.S., Gown A.M., and Schnitt S.J. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 30 (2006) 1002-1007
24. Tse GMK, Tan PH, Lui PCW, et al. The role of immunohistochemistry for smooth muscle actin, p63, CD10 and CK14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 2006; doi:10.1136/jcp.2006.036830 12 May 2006.
25. Tan P.H., Aw M.Y., Yip G., et al. Cytokeratins in papillary lesions of the breast. Is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ. Am J Surg Pathol 29 (2005) 625-632
26. Rabban J.T., Koerner F.C., and Lerwill M.F. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol 37 (2006) 787-793
27. Ribeiro-Silva A., Zamzelli Ramalho L.N., Garcia S.B., and Zucoloto S. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast. Pathol Oncol Res 9 (2003) 20-23
28. Kalof A.N., Tam D., Beatty B., and Cooper K. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol 57 (2004) 625-629
29. Goldstein N.S., Bassi D., Watts J.C., Layfield L.J., Yaziji H., and Gown A.M. E-cadherin reactivity of 95 invasive ductal and lobular lesions of the breast: implications for the interpretation of problematic lesions. Am J Clin Pathol 115 (2001) 534-542
30. Bratthauer G.L., Moinfar F., Stamatakos M.D., et al. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Hum Pathol 33 (2002) 620-627
31. Bratthauer G.L., Miettinen M., and Tavassoli F.A. Cytokeratin immunoreactivity in lobular intraepithelial neoplasia. J Histochem Cytochem 51 (2003) 1527-1531
32. Nielson T.O., Hsu F.S., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
33. Rakka E.A., Putti T.C., Abd El-Rehim D.M., et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208 (2006) 495-506
34. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51 (1998) 227-238
35. Elledge R.M., Green S., Pugh R., et al. Estrogen receptor (ER) and progesterone receptor (PgR) by ligand binding assay compared with ER, PgR and pS2 by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89 (2000) 111-117
36. Harvey J.M., Clark G.M., Osborne C.K., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to ligand-binding assay for predicting response to adjuvant therapy in breast cancer. J Clin Oncol 17 (1999) 1474-1481
37. Osborne C.K., Schiff R., Arpino G., Lee A.S., and Hilsenbeck V.G. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 14 (2005) 458-465
38. McCarty Jr. K.S., Miller L.S., Cox E.B., et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal anti-receptor antibodies. Arch Pathol Lab Med 109 (1985) 716-721
39. Barnes D.M., Harris W.H., Smith P., Millis R.R., and Rubens R.D. Immunohistochemical determination of oestrogen receptor; comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74 (1996) 1445-1451
40. McClelland R.A., Wilson D., Leake R., Finlay P., and Nicholson R.I. A multicentre study into the reliability of immunocytochemical assay quantification. Eur J Cancer 27 (1991) 711-715
41. Fritz P., Wu X., Tuczek H., Multhaupt H., and Schwarzmann P. Quantification in immunohistochemistry. A research method or diagnostic tool in surgical pathology?. Pathologica 87 (1995) 300-309
42. Slaman D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235 (1987) 177-182
43. Varley J.M., Swallow J.E., Brammar W.J., Whittaker J.L., and Walker R.A. Alterations to either c-erbB-2 (neu) or c-myc protooncogenes in breast carcinomas correlated with poor short-term prognosis. Oncogene 1 (1987) 423-430
44. Harries M., and Smith J. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9 (2002) 75-85
45. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
46. Ramond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
47. Ellis I.O., Dowsett M., Humphreys S., et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol 57 (2004) 233-237
48. Nicholson R.I., Hutchinson I.R., Harper M.E., et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8 (2001) 175-182
49. Tanner M., Isola J., Wikland T., et al. Topoisomerase II alpha gene amplification predicts favourable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24 (2006) 2428-2436